Anavex Life Sciences Corp (AVXL)

[Hosai]

"In your scenario, Anavex is a binary event. In three or more years Blarcamesine for AD either succeeds or fails. That’s a huge risk that some retail investors might be willing to take but institutional biotech investors will likely not take."

That is the same risk that every pre-revenue biotech has. Clearly institutional biotech investors do indeed take on such risks for the potential huge rewards.